Cardiovascular outcomes trials of early CETP inhibitors, including torcetrapib, dalcetrapib, and evacetrapib, were unsuccessful in demonstrating reduced risk of ASCVD for a variety of agent-specific, not class-specific, reasons [1, 22–27]. This evidence concerns the gene CETP and atherosclerosis.